Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 15/20 | 1.00 |
| ▸ | EPHX2 | P34913 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1059134 | 1.00 | EPHX1 (1.00) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL12196092 | 1.00 | EPHX1 (1.00) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL7561514 | 1.00 | EPHX1 (1.00) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL8395090 | 1.00 | EPHX1 (1.00) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL652844 | 1.00 | EPHX1 (1.00) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL12196099 | 1.00 | EPHX1 (1.00) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL12196095 | 1.00 | EPHX1 (1.00) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL2752706 | 0.98 | EPHX1 (0.97) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL7440101 | 0.98 | EPHX1 (1.00) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL2753457 | 0.98 | EPHX1 (0.97) | EPHX1EPHX2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200278346-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ADJACENT ACQUISITION CO., LLC | 2020-09-03 | — | — | US | disclosed |
| EP-3681504-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | Icagen, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2019055754-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| US-20150309021-A1 | Advanced Drug Development and Manufacturing | LOS ALAMOS NATIONAL SECURITY, LLC | 2015-10-29 | — | — | US | disclosed |
| EP-2511844-A2 | Advanced drug development and manufacturing | Los Alamos National Security, LLC (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-2084519-B1 | X-RAY FLUORESCENCE ANALYSIS METHOD | LOS ALAMOS NAT SECURITY LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20110245331-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF HYPERTENSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110245331-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF HYPERTENSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110021448-A1 | Inhibitors for the Soluble Epoxide Hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-27 | — | — | US | disclosed |
| US-7662910-B2 | Inhibitors for the soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-02-16 | — | — | US | disclosed |
| US-20090326039-A1 | INHIBITORS FOR THE SOLUBLE EPOXIDE HYDROLASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-12-31 | — | — | US | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| US-20070117782-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF INFLAMMATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070117782-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF INFLAMMATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326039-A1 | INHIBITORS FOR THE SOLUBLE EPOXIDE HYDROLASE | EPHX1, EPHX2, NCEH1 | EPHX1 1/4885EPHX2 2/4885KDM4E 2177/4885 |
| US-20110245331-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF HYPERTENSION | EPHX1, EPHX2, NCEH1 | EPHX1 1/4885EPHX2 2/4885KDM4E 920/4885 |
| US-20110021448-A1 | Inhibitors for the Soluble Epoxide Hydrolase | EPHX1, EPHX2, NCEH1 | EPHX1 1/4885EPHX2 2/4885KDM4E 2177/4885 |
| US-20070117782-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF INFLAMMATION | EPHX1, LTA4H, PTGS1 | EPHX1 1/4885EPHX2 4/4885KDM4E 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.